Related Experiment Videos
Cardiogenic Shock Following Acute Myocardial Infarction: What's New?
Martino Pepe1, Alessandro Santo Bortone2, Arturo Giordano3,4
1Division of Cardiology, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy.
Insights
Cardiogenic shock (CS) following acute myocardial infarction (AMI) has high mortality despite treatments. New European guidelines review revascularization and mechanical support, but further research is needed for optimal CS management.
Area of Science:
- Cardiology
- Critical Care Medicine
Background:
- Cardiogenic shock (CS) is a severe complication of acute myocardial infarction (AMI), characterized by end-organ hypoperfusion due to cardiac dysfunction.
- Despite advancements in revascularization, medical therapy, and mechanical circulatory support, CS continues to have a high mortality rate.
Purpose of the Study:
- To review the epidemiology, pathophysiology, and treatment strategies for CS.
- To incorporate the latest European Society of Cardiology (ESC) guidelines regarding myocardial revascularization and mechanical support in AMI-related CS.
Main Methods:
- Review of current evidence, including randomized trials and observational registries.
- Analysis of recent studies on novel mechanical circulatory support devices.
- Consideration of updated European guidelines on AMI management.
Main Results:
- Recent guidelines have updated recommendations on early multivessel revascularization and the routine use of intra-aortic balloon pumps (IABP) in AMI-related CS.
- Emerging mechanical circulatory support devices show potential benefits, but require further evidence to establish their risk-benefit ratio.
- Significant knowledge gaps persist regarding optimal medical, reperfusion, and circulatory support strategies.
Conclusions:
- Cardiogenic shock remains a critical condition with high mortality post-AMI.
- While guidelines and new technologies offer advancements, further clinical trials are essential to optimize patient outcomes and address unanswered questions in CS management.
Abstract:
Cardiogenic shock (CS) is a state of critical end-organ hypoperfusion primarily due to cardiac dysfunction. This condition is the most common cause of death in patients affected by acute myocardial infarction (AMI). Despite early revascularization, prompt optimal medical therapy, and up-to-date mechanical circulatory supports, mortality of patients with CS remains high.The objective of this review is to summarize epidemiology, pathophysiology, and treatment options of CS in light of the new European Society of Cardiology (ESC) recommendations. The latest European guidelines on myocardial revascularization have reviewed the previous guidelines with respect to early multivessel revascularization and routine use of intra-aortic balloon pump (IABP) in patients with AMI-related CS.Most of the current evidences come partly from randomized trials, but mostly from observational registries because of the difficulty to test different treatments in this life-threatening clinical setting.Some of the latest studies highlight the potential crucial benefit of newly introduced mechanical circulatory support devices, although evidences are not sufficient to definitely assess the benefit/risk ratio of the different systems.Many questions remain unanswered in this field, and further trials are advocated to better elucidate the best medical, reperfusion, and circulatory support approaches aimed to improve the poor prognosis of patients with CS after AMI.